McCarthy D M, Kanfer E J, Barrett A J
Department of Haematology, Charing Cross and Westminster Medical School, London, UK.
Biomed Pharmacother. 1989;43(9):693-7. doi: 10.1016/0753-3322(89)90089-9.
The immunosuppressive effects of the sedative drug thalidomide have been utilised in a variety of immune disorders. In the present study, 6 patients were treated who developed graft-versus-host disease (GvHD) following allogeneic bone marrow transplantation (BMT) with thalidomide and in a dose range of 200-600 mg daily. Two of 3 patients with chronic GvHD showed clear improvement, whereas none of the 3 patients with acute GvHD derived unequivocal benefit. Although based on a small number of patients, these data suggest that thalidomide may find a useful place in the therapy of GvHD, perhaps specifically in the chronic form of this disorder.
镇静药物沙利度胺的免疫抑制作用已被应用于多种免疫紊乱疾病。在本研究中，6例在接受异基因骨髓移植（BMT）后发生移植物抗宿主病（GvHD）的患者接受了沙利度胺治疗，剂量范围为每日200 - 600毫克。3例慢性GvHD患者中有2例病情明显改善，而3例急性GvHD患者均未获得明确益处。尽管基于少数患者，但这些数据表明沙利度胺可能在GvHD治疗中发挥有益作用，或许特别是在这种疾病的慢性形式中。
